Race is on to develop new generation of weight-loss drugs
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions